Sermonix Pharmaceuticals Inc.

Sermonix used the Tempus TIME Trial® Network to enroll 45% of its ELAINE-2 patientsThe company is again partnering with Tempus to enroll patients in its Phase 3 ELAINE-3 study COLUMBUS, Ohio, June 26, 2023 (GLOBE NEWSWIRE) -- Sermonix…

CHICAGO, June 05, 2023 (GLOBE NEWSWIRE) -- Sermonix Pharmaceuticals Inc., a privately held biopharmaceutical company developing innovative therapeutics to specifically treat metastatic breast cancers harboring ESR1 mutations, today…

COLUMBUS, Ohio, Nov. 17, 2022 (GLOBE NEWSWIRE) -- Sermonix Pharmaceuticals Inc., a privately held biopharmaceutical company developing innovative targeted therapeutics to specifically treat ESR1-mutated metastatic breast and…

Presentation delivered at the ninth-annual Metastatic Breast Cancer Research Conference in Park City, Utah Case was reported during Phase 2 study investigating efficacy of lasofoxifene, Sermonix’s lead investigational drug COLUMBUS, Ohio,…

COLUMBUS, Ohio, June 09, 2022 (GLOBE NEWSWIRE) -- Sermonix Pharmaceuticals Inc., a privately held biopharmaceutical company developing innovative therapeutics to specifically treat ESR1-mutated metastatic breast and gynecological…

Guiding Researchers and Advocates to Scientific Partnerships (GRASP) launched in 2019 to unite patient advocates, physicians and researchers through meaningful discussions of cancer-related topicsSermonix’s poster detailing the Phase 2…

COLUMBUS, Ohio, May 31, 2022 (GLOBE NEWSWIRE) -- Sermonix Pharmaceuticals Inc., a privately held biopharmaceutical company developing innovative therapeutics to specifically treat ESR1-mutated metastatic breast and gynecological cancers,…